Weiss Multi-Strategy Advisers
PRVL

Weiss Multi-Strategy Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,061
Closed -$717K – 926
2020
Q4 		$717K Buy
+31,061
New +$394K 0.01% 523

Weiss Multi-Strategy Advisers's PRVL Position: Q1 2021 in Review

Weiss Multi-Strategy Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 31,061 shares — an estimated $717K sold.

Weiss Multi-Strategy Advisers first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $717K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Weiss Multi-Strategy Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 31,061 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $717K.
  • Weiss Multi-Strategy Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $717K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2021, filed 14 May 2021.